Table of Contents
Dr. Reddys Lab Business Overview
Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company that offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars, and differentiated formulations.
Dr. Reddys Lab Financial Performance
| FY 2022 | FY 2023 | FY 2024 | |
|---|---|---|---|
| Revenue | 21,545 | 24,670 | 28,011 |
| Expense | 17,778 | 18,200 | 20,078 |
| OPM (%) | 17% | 26% | 28% |
| Net income | 2,182 | 4,507 | 5,578 |
| EPS | 131.14 | 270.66 | 334.37 |
Dr. Reddys Lab Financial Ratios
| PE Ratio | ROCE | ROE | PEG Ratio |
| 19.6 | 26.5 % | 21.4 % | 0.80 |
| Book Value | ROA | Debt to equity | Piotroski score |
| ₹ 1,694 | 15.5 % | 0.07 | 6.00 |
Dr. Reddys Lab Peer comparison
| PE ratio | ROCE % | OPM % | |
|---|---|---|---|
| Cipla | 29.83 | 22.80 | 24.92 |
| Sun Pharma | 42.44 | 17.32 | 27.03 |
| Dr Reddys Lab | 19.63 | 26.53 | 27.61 |
| Lupin | 43.39 | 15.72 | 20.16 |
Indian Stock market has grown over the last couple of decades. However, little has gone towards bolstering the participation of retail investors in the market. Through its unbiased approach of dissecting the prevalent challenges and finding ways for small investors to make money, Stock Market Dekho aims to help individual investors along their stock market journey.
Disclaimer: No content on this website should be treated as investment advice. All the content offered on the website is for informational purposes only. Please contact your adviser before making an investment.
Contact Us:- admin@stockmarketdekho.in
Pages
Follow us
Proudly powered by WordPress